and a 36-month beta value of 1.17.
The average price predicted for Nektar Therapeutics (NKTR) by analysts is $2.93, which is $1.79 above the current market price. The public float for NKTR is 185.37M, and at present, short sellers hold a 4.72% of that float. On March 16, 2023, the average trading volume of NKTR was 2.07M shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
NKTR) stock’s latest price update
Nektar Therapeutics (NASDAQ: NKTR)’s stock price has decreased by -5.00 compared to its previous closing price of 1.20. However, the company has experienced a -10.24% decline in its stock price over the last five trading sessions.
NKTR’s Market Performance
NKTR’s stock has fallen by -10.24% in the past week, with a monthly drop of -62.99% and a quarterly drop of -57.93%. The volatility ratio for the week is 7.76% while the volatility levels for the last 30 days are 8.42% for Nektar Therapeutics The simple moving average for the last 20 days is -41.10% for NKTR stock, with a simple moving average of -65.38% for the last 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Underperform.” The predicted price for NKTR in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 24th of the current year 2023.
Jefferies gave a rating of “Hold” to NKTR, setting the target price at $4 in the report published on May 31st of the previous year.
NKTR Trading at -51.06% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.17% of loss for the given period.
Volatility was left at 8.42%, however, over the last 30 days, the volatility rate increased by 7.76%, as shares sank -62.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.56% lower at present.
During the last 5 trading sessions, NKTR fell by -10.24%, which changed the moving average for the period of 200-days by -67.05% in comparison to the 20-day moving average, which settled at $1.8415. In addition, Nektar Therapeutics saw -49.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 19,635 shares at the price of $3.00 back on Feb 16. After this action, ROBIN HOWARD W now owns 960,158 shares of Nektar Therapeutics, valued at $58,905 using the latest closing price.
Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sale 10,484 shares at $3.00 during a trade that took place back on Feb 16, which means that Zalevsky Jonathan is holding 303,179 shares at $31,452 based on the most recent closing price.
Stock Fundamentals for NKTR
Equity return is now at value -79.80, with -43.60 for asset returns.
Conclusion
To sum up, Nektar Therapeutics (NKTR) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
